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Cell transformationCdc42 is a Ras-related small GTP-binding protein. A previous study has shown that Cdc42 binding to
the c subunit of the coatomer protein complex (cCOP) is essential for Cdc42-regulated cellular
transformation, but the molecular mechanism involved is not well understood. Here, we demon-
strate that constitutively-active Cdc42 binding to cCOP induced the accumulation of epithelial
growth factor receptor (EGFR) in the cells, sustained EGF-stimulated extracellular signal-regulated
kinase (ERK), JUN amino-terminal kinase (JNK) and phosphoinositide 3-kinase (PI3K) signaling
and promoted cell division. Moreover, constitutive Cdc42 activity facilitated the nuclear transloca-
tion of EGFR, and this indicates a novel mechanism through which Cdc42 might promote cellular
transformation.
 2014 The Authors. Published by Elsevier B.V. on behalf of the Federation of European Biochemical
Societies. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/3.0/).1. Introduction
The Ras-related GTP-binding protein Cdc42 has been implicated
in a variety of biological activities, including the establishment of
cell polarity, regulation of cell morphology, motility, cell cycle pro-
gression, intracellular trafﬁcking and induction of malignant trans-
formation [1–3]. Like other members of the Rho subfamily, Cdc42
was initially implicated in the regulation of the actin cytoskeletal
architecture. In particular, the microinjection of activated forms
of Cdc42 were shown to cause ﬁlopodia formation whereas acti-
vated Rac1 stimulated the formation of lamellipodia and activated
RhoA promoted actin stress ﬁbers [4–6]. Subsequently, several dif-
ferent lines of research have implicated Cdc42, as well as other
Rho-family proteins, in the control of normal cell growth or, when
aberrantly regulated, in tumorigenesis and metastasis [7]. Wu et al.
reported that when they searched for new Cdc42 targets in an
effort to understand how Cdc42 mediates cellular transformation.They identiﬁed the c-subunit of the coatomer complex (cCOP) as
a speciﬁc binding partner for activated Cdc42. This complex is
important in intracellular trafﬁcking. The binding of Cdc42 to cCOP
is essential for cellular transformation [8]. However, the speciﬁc
molecular mechanism remains to be deﬁned.
Emerging evidence suggested that cell surface receptors, such
as the entire epidermal growth factor receptor (EGFR) family, local-
ize in the nucleus. EGF-dependent nuclear transport of EGFR is
associated EGFR with cCOP [9,10]. Nuclear EGFR has been shown
to be involved in transcriptional regulation, cell proliferation,
DNA repair, DNA replication and chemo-resistance [11].
Cdc42 regulates actin dynamics and control Golgi-to-ER protein
transport [12]. Shiga-toxin-producing Escherichia coli remain a
food-borne health threat. ARHGAP 21 and Cdc42-based signaling
regulates the dynein-dependent retrograde transport of Shiga
toxin to the Golgi apparatus [13]. However, whether Cdc42 can
regulate nuclear transport of EGFR still has not been investigated.
To answer this question, we stably expressed constitutively active
Cdc42 mutant Cdc42(F28L) and Cdc42(F28Lss) mutant which
breaking Cdc42 and cCOP binding and blocking intracellular traf-
ﬁcking in NIH 3T3 cells. We found that NIH 3T3 cells stably
expressing Cdc42(F28L) exhibited signiﬁcantly higher levels of
EGFR and a markedly extended lifetime for EGFR-coupled signaling
in response to EGF and showed nuclear accumulation of EGFR.
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showed much less levels of EGFR in the cytoplasm and almost no
accumulation of EGFR in nuclei of the cells, and thus inhibited
transformed phenotype.2. Materials and methods
2.1. Reagents and antibodies
The epidermal growth factor (EGF) was from Calbiochem.
Monoclonal antibody to EGF receptor was from BD Transduction
Laboratory. Phospho-Akt (Ser473), phospho-SAPK/JNK (Thr183/
Tyr185) and phospho-p44/p42 MAPK (Thr202/Tyr204), were
obtained from Cell Signaling Technology. Anti-BrdU antibody was
from Sigma. Oregon-Green-conjugated goat anti-mouse IgG and
Rhodamine-Red-conjugated goat anti-rabbit IgG, and Tetramethyl-
rhodamine-labeled EGF were purchased from Molecular Probes.
Texas Red-conjugated philloidin and anti-vinculin antibodies were
from Sigma, and Oregon Green-conjugated anti-mouse antibody
was from Molecular Probes. The Oregon-Green-conjugated goat
anti-mouse antibody was used to detect HA-tagged Cdc42(F28L),
and Rhodamine-Red-conjugated goat anti-rabbit antibody to
detect GM130(H-65), monoclonal antibody to HA was from Cov-
ance and a rabbit polyclonal antibody to GM130 (a 130kDa cis-
Golgi matrix protein) was from Santa Cruz.
2.2. Stable cell lines
The empty vector (pCDNA3-Neo) alone, or was cotransfected
with pJ4H-Cdc42(F28L), or pJ4H-Cdc42(F28Lss) in NIH 3T3 cells.
Transfected cells were maintained in Dulbecco modiﬁed Eagle
medium (DMEM) (Invitrogen) supplemented with 5% calf serum
and 700 lg/ml G418 (Invitrogen). After 10–14 days, G418-resistant
colonies were selected.
2.3. Cell culture, immunobloting, immunoﬂuorescence microscopy and
assays for cellular transformation
Cell culture, Western blot, immunoﬂuorescence microscopy and
the detailed procedures for cellular transformation assays includ-
ing growth in low serum, saturation density and soft agar were car-
ried out as previously described [1].
2.4. Analysis of EGFR, ERK, Akt and JNK activation
NIH 3T3 cells stably expressing Cdc42(F28L), Cdc42(F28Lss) or
vector control cells were seeded to 60-mm plates. Following over-
night incubation in serum-free media, cells were stimulated with
EGF for 5 min, 15 min, 45 min and 2 h or were left untreated, and
then the cell lysates were harvested. Equivalent amounts of protein
(50–80 lg) were subjected to SDS–PAGE, followed by Western blot
using anti-EGFR, phospho-ERK, phospho-Akt, and phospho-JNK
antibodies.
2.5. EGF receptor endocytosis assay
Vector control NIH 3T3 cells, and cells stably expressing
Cdc42(F28L) or Cdc42(F28Lss) mutants were seeded on dual cham-
ber slides and serum-starved for 12 h prior to exposure to tetram-
ethylrhodamine-labeled EGF (0.5 lg/ml) at 4 C for 1 h. Cells were
warmed to 37 C for the indicated times, transferred to ice, and
stripped to remove surface bound EGF by stripping buffer, then
washed with 1 PBS and ﬁxed before being observed by
microscope.2.6. Cell proliferation assay
To assay BrdU incorporation, NIH 3T3 cells stably expressing
Cdc42(F28L) or Cdc42(F28Lss) were plated in 60-mm plates. Early
next morning, changed the normal culture medium to 2% calf
serum in DMEM without antibiotics for about 18 h. At the end of
18 h starvation, cells were trypsinized and replated in steriled
chamber slides. BrdU was added to the medium, 14–16 h later,
cells were processed for immunoﬂuorescence staining with anti-
BrdU monoclonal antibody, anti-HA polyclonal antibody, and Hoe-
chst as described previously [14]. The percentage of BrdU positive
cells was determined for more than 600 cells from multiple ﬁelds
of each experiment.
2.7. Cellular fractionation
Nuclear fractions were isolated via NE-PER nuclear and cyto-
plasmic extraction reagents (Thermo). In brief, cultured cells were
harvested and resuspended in ice-cold CER I. Cells were vortexed
vigorously and incubated on the ice, then were added ice-cold
CER II, vortexed again and centrifuged. The resulting supernatant
was the cytoplasmic extract. The pellet fraction was suspended
in ice-cold CER and centrifuged. The nuclear extract fractions were
then collected.
3. Results
3.1. Breaking Cdc42 and cCOP binding inhibits transformed
phenotypes
There are two consecutive lysine residues within the Cdc42 C-
terminal region at positions 183 and 184. Mutating these lysine
residues to serine (Cdc42(F28Lss)) eliminated the binding of
Cdc42 to the cCOP [12]. NIH 3T3 cells were stably expressed
Cdc42(F28L), Cdc42(F28Lss) or vector control and analyzed for
their ability to grow under different conditions (Western blots of
the different constructs were shown in Fig. 1A, lower panel; H, M
and L denote different cell lines exhibiting higher, medium and
lower stable expression, respectively, of a particular construct).
The upper panel in Fig. 1A shows the results of cell growth assay
performed in low serum. NIH 3T3 cells expressing the constitu-
tively active, fast-cycling Cdc42(F28L) mutant were extremely
effective at growing in low serum whether their expressions were
in higher, medium and lower levels. As compared to Cdc42(F28L),
Cdc42(F28Lss) mutants in different expression levels were unable
to grow under these conditions over the course of 2, 4, and 6 days.
The vector control ﬁbroblasts grew also very slow.
Similar results were obtained when examining the relative abil-
ity of the Cdc42 constructs to enable ﬁbroblasts to increase their
saturation density and to form colonies in soft agar (Fig. 1B and
C). In each case, Cdc42(F28Lss) elicited a four times less transform-
ing phenotype than Cdc42(F28L) approximately whether the
expression were in higher, medium or lower levels. These results
indicate that disrupting the interaction between constitutively
active Cdc42 and the coatomer subunit cCOP inhibits transformed
phenotypes.
3.2. Cdc42(F28Lss) and Cdc42(F28L) stimulate ﬁlopodia formation and
share similar subcellular localization
In order to determine the cellular mechanism by which
Cdc42(F28Lss) inhibits transformed phenotypes, we examined
whether the Cdc42(F28Lss) mutant altered its ability to stimulate
the actin cytoskeletal changes that have been previously associated
with the activation of this GTP-binding protein. One important
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Fig. 1. Cdc42(F28Lss) mutant is unable to cause cellular transformation. (A) Growth in low serum. NIH 3T3 cells stably expressing Cdc42(F28L), Cdc42(F28Lss), or vector
control cells were cultured in DMEM supplemented with 1% calf serum (low serum). At the indicated times, cells were trypsinized and counted. Data represent the average of
three independent experiments. The lower images showWestern blots comparing the relative expression of indicated constructs in whole cell lysates. H, M and L refer to cell
lines that exhibit higher, medium and lower levels, respectively, of the stable expression of the particular protein of interest. (B) Saturation density assays. The indicated cell
lines were cultured in DMEM supplemented with 10% calf serum for 6 days, trypsinized and counted. Data represent the average of three independent experiments. (C) Soft
agar assays. Cells stably expressing the indicated constructs were mixed with DMEM supplemented with 03% agarose and 10% calf serum and plated on top of DMEM
supplemented with 05% agarose and 10% calf serum. Colonies were scored after 14 days of growth. The data shown are the average of three independent experiments. 100%
represents 500 cells counted.
X.-Y. Wang et al. / FEBS Letters 589 (2015) 255–262 257characteristic for Cdc42 activation is the induction of ﬁlopodia
[15]. We found that both Cdc42(F28L) and Cdc42(F28Lss) induced
spike-like extensions (ﬁlopodia) into the surrounding medium in
the majority of NIH 3T3 cells examined comparing with the vector
control cells (Fig. 2A upper panel). This suggests that although
Cdc42(F28LSS) can not induce cellular transformation, it still
exhibits Cdc42 activity. Multi-molecular focal adhesion complexes
associated with the plasma membrane are found in ﬁlopodia and
lamellipodia induced by Cdc42 and Rac [16]. We also checked
whether focal adhesion complex formation changed between the
two constructs and found that they were unable to distinguish as
both constructs induced this phenotype (Fig. 2A lower panel).
We next investigated whether subcelluar localization of
Cdc42(F28Lss) changes comparing with Cdc42(F28L). The subcel-
lular distribution of Cdc42 was determined by confocal micro-
scope, both Cdc42(F28Lss) and Cdc42(F28L) showed a prominent
perinuclear staining pattern, as detected by the anti-HA antibody
(red) (Fig. 2B). The observation revealed that Cdc42(F28Lss) and
Cdc42(F28L) may be present in the Golgi. To conﬁrm this idea,
the Golgi speciﬁc marker GM130 was used (green). The merged
images (yellow) proved that Cdc42(F28Lss) and Cdc42(F28L) share
similar subcellular localization in Golgi (Fig. 2B).3.3. The EGF receptor is not accumulated in cells stably expressing
Cdc42(F28Lss)
EGFR is a receptor tyrosine kinase involved in normal cell
growth and differentiation as well as in the pathogenesis of cancer
[17]. Previous studies showed that EGFR after endocytosis, are tar-
geted for degradation via an ubiquitination reaction catalyzed by
the Cbl adaptor proteins. Activated Cdc42 binds to p85Cool-1, a
protein that directly associates with c-Cbl. This inhibits the binding
of Cbl by the EGFR and leads to their aberrant accumulation and
cellular transformation [18]. We found that Cdc42(F28Lss) mutant
could still bind to p85Cool-1, then p85Cool-1 bound to Cbl to form
a complex (data not show). Theoretically, EGFR should be accumu-
lated in the cells. However, following the addition of EGF to NIH
3T3 cells expressing Cdc42(F28Lss) or Cdc42(F28L), total receptor
levels in Cdc42(F28Lss) expressing cells as detected by Western
blot with an anti-EGFR antibody were very low at all time points
except a little bit higher at 0 min. Cells stably expressing
Cdc42(F28L) showed a dramatic increase of EGFR. Additionally,
the turnover of EGFR was very slow because EGFR was still
detected after 2 h of incubation with EGF. The EGFR level in vector
control ﬁbroblasts was also much lower than that in NIH 3T3 cells
APhalloidin-red
Anti-Vinculin
Cdc42(F28L) Cdc42(F28Lss) Vector
Cdc42(F28L) Cdc42(F28Lss) B 
Anti-HA
Anti-GM130(H-65) 
Fig. 2. Cdc42(F28Lss) and Cdc42(F28L) stimulate ﬁlopodia formation and share similar subcellular localization. (A) The indicated stable cell lines were cultured on
microscope chambers and ﬁxed with 3.7% formaldehyde. Filamentous actin structures were visualized using Texas Red-conjugated Phalloidin, focal adhesion complexes were
visualized with anti-vinculin antibody followed by Oregon Green conjugated anti-mouse IgG (Molecular probes). Treated slides were observed under a immunoﬂuorescence
microscope. (B) The confocal microscope was used to check subcellular localization of Cdc42 mutants. The NIH 3T3 cells stably expressing Cdc42(F28L), Cdc42(F28Lss) or
vector control were ﬁxed, permeabilized and incubated with antibodies against HA (red) and anti-GM130 (H-65) (anti-Golgi antibody) (green). Cells were treated with DAPI
to visualize nuclei (blue) and composite colocalization of all three images are shown. Colocalization (yellow) of Cdc42 mutants and Golgi is detected.
258 X.-Y. Wang et al. / FEBS Letters 589 (2015) 255–262expressing Cdc42(F28L) (the upper three panels of Fig. 3A). The
similar results were got for lower expression cell lines (Fig. 3A mid-
dle three panels). The lower three panels of Fig. 3A shows sepa-
rately that the same amount of proteins detected by anti-actin
were loaded to SDS–PAGE in different samples. Therefore, disrupt-
ing the interaction between constitutively active Cdc42 and the
coatomer subunit cCOP leads to down-regulation of EGFR total cel-
lular level.
We conﬁrmed further that EGFR was not accumulated in cells
expressing Cdc42(F28Lss) by using immunoﬂuorescence micros-
copy. Fig. 3B shows the rhodamine-labeled EGF bound to the
receptor, as a function of time of treatment with the labeled
growth factor. In cells expressing Cdc42(F28Lss), EGFR levels were
signiﬁcantly reduced within 15 min of treatment with labeled EGF.
However, in cells expressing Cdc42(F28L), EGFR were detected and
accumulated in endosomal compartments through 2 h of treat-
ment with labeled EGF. In contrast, EGFR accumulation was not
observed in vector control cells treated with EGF for more than
5 min.
3.4. Cdc42(F28Lss) mutant fails to induce ERK, JNK and PI-3K
activation
For mammalian cells, MAP kinases represent a family of Ser/Thr
protein kinases and are comprised of three distinct components:
ERKs, JNKs and p38, they are regulated by EGFR. In different cell
lines, these kinases have been shown to play important roles inregulating cell growth [19]. Cdc42 initiates a protein kinase cas-
cade that leads to activation of MAP kinases [20]. To determine
whether the inhibitory effect of Cdc42(F28Lss) on transformed
phenotypes is associated with its ability to block MAP kinases
activity. We performed time-course experiments. NIH 3T3 cells
stably expressing Cdc42(F28Lss), Cdc42(F28L) and vector control
cells were serum starved overnight, then stimulated with EGF for
different times. Fig. 4A shows that in NIH 3T3 cells stably express-
ing Cdc42(F28Lss) and vector control cells, the activation of ERK as
examined by phosphor-p42/p44 ERK antibody was peaked within
5 min, but rapidly diminished for 15–45 min after exposure to
EGF. Conversely, in NIH 3T3 cells stably expressing Cdc42(F28L),
EGF-stimulated ERK activation could be detected up to 2 h of incu-
bation with EGF. The same amount of proteins were loaded to SDS–
PAGE in different samples (Fig. 4A lower panel). Similar results
were obtained for JNK activation (Fig. 4B).
PI-3K is a ubiquitously expressed enzyme that plays a critical
role in the regulation of many cellular processes including cellular
transformation [21]. In the ﬁbroblasts stably expressing
Cdc42(F28Lss) or vector control cells, EGF-stimulated activation
of Akt, a key downstream effector of PI-3K, could be detected just
within 5 min and then disappeared for any longer incubation with
EGF. However, in ﬁbroblasts stably expressing Cdc42(F28L), the
EGF-induced Akt activation peaked within 5 min, then reduced
gradually between the span of 5 min-2 h (Fig. 4C). The same
amount of proteins were loaded to SDS–PAGE in different samples
(Fig. 4A lower panel).
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Fig. 3. The EGF receptor is not accumulated in cells stably expressing Cdc42(F28Lss). (A) The upper three and middle three panels show NIH 3T3 cells stably expressing
Cdc42(F28L), Cdc42(F28Lss) in higher and lower levels, respectively, or vector control cells. Cells were seeded in 6-well plates and serum starved for 12 h prior to EGF (100 ng/
ml) stimulation for the indicated times at 37 C. The levels of EGF receptor were assessed byWestern blot analysis of the cell extracts using an anti-EGF receptor antibody. The
expression of the different Cdc42 constructs was identical in the different cell lines (see Fig. 1A lower image). Lower three panels show that the same amount of proteins were
loaded to SDS–PAGE in different samples using anti-actin antibody. (B) Vector control NIH 3T3 cells, cells stably expressing Cdc42(F28L) or Cdc42(F28Lss) were seeded on
dual chamber slides and serum starved for 12 h prior to exposure to tetramethylrhodamine labeled EGF (0.5 lg/ml) at 4 C for 1 h. Cells were warmed to 37 C for the
indicated times, transferred to ice, and stripped to remove surface bound EGF. The red punctated structures indicate tetramethylrhodamine labeled EGF receptor.
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Fig. 4. The effects of Cdc42(F28Lss) on EGF-stimulated ERK, JNK and PI-3K activities. Time course experiments. Following serum starvation overnight, NIH 3T3 cells stably
expressing Cdc42(F28L), Cdc42(F28Lss) or vector control cells were stimulated with EGF (100 ng/ml) for the indicated times. Anti-phospho-p44/42 ERK antibody was used to
detect activated p44/p42 ERK (A); or anti-phospho-JNK antibody to detect activated JNK (B); or anti-phospho-Akt antibody was used to detect activated PI3K (C).
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Given the signiﬁcance of Cdc42(F28L) in mediating cellular
transformation, we were wondering whether Cdc42(F28Lss)
mutant blocks transformed phenotypes because it inhibits cell
proliferation. In BrdU assay, the levels of DNA synthesis in NIH
3T3 cells stably expressing Cdc42(F28Lss), were reduced two
times comparing with those of NIH 3T3 cells stably expressing
Cdc42(F28L) approximately (Fig. 5A and B). Therefore,
Cdc42(F28Lss) mutant should be directly or indirectly inhibit cellu-
lar transformation by inﬂuencing cell cycle progression.
3.6. Cdc42(F28L) mutant promotes EGFR nuclear transport
Emerging evidences indicate that EGFR has been shown to
localize in the nucleus of various malignant tumors [22,23]. We
want to know whether Cdc42 can promote nuclear transport of
EGFR in Cdc42(F28L) transformed cells. To address this issue, pro-
teins were isolated from the cytosolic and nuclear compartments
and separated by SDS–PAGE and examined by subsequent immu-
noblotting to determine the effects of Cdc42 mutants on EGFR
localization. As shown in Fig. 6A, ten times EGFR was appeared
in the nuclei of cells expressing Cdc42(F28L) than that of the cells
expressing Cdc42(F28Lss) approximately.
Next, we performed confocal microscopy to conﬁrm the distri-
bution of EGFR in the nuclei of different cells (Fig. 6B). NIH 3T3
cells stably expressing Cdc42(F28L), Cdc42(F28Lss) or vector con-
trol cells were immunostained with EGF receptor antibody (red)
and DAPI for nuclei (blue). The nuclei of Cdc42(F28L) expressing
cells were stained in red color much stronger than those of
Cdc42(F28Lss) expressing cells. When merged, the nuclei ofCdc42 (F28L)
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Fig. 5. Cdc42(F28Lss) mutant blocks cell cycle progression. BrdU incorporation assays we
The percentage of cells incorporating BrdU after 18 h is shown. Data represent the
photomicrographs of the cells stained with anti-BrdU and their nuclei stained with HoeCdc42(F28L) cells were in a purple color; but the nuclei of
Cdc42(F28Lss) were still in blue color. This suggested again that
more EGFR was localized in the nuclei of Cdc42(F28L)-expressing
cells than Cdc42(F28Lss)-expressing cells (Fig. 6B, left: single cell
images; right: multiple cells images).
4. Discussion
EGFR is involved in numerous aspects of cell growth, survival,
differentiation, migration and invasion [24,25]. EGFR regulates
these diverse cell functions through interacting with and activating
a number of downstream signaling proteins that organize multi-
layered, distinctive, and interconnected signaling pathways
[26,27]. The magnitude and duration of these signaling pathways
as well as their spatial distribution all need to be delicately con-
trolled; slight aberrations, such as EGFR overexpression or muta-
tional activation or aberrant activation of downstream effectors,
have been linked to the pathogenesis of cancer [28].
Cdc42 is a member of the Rho family GTPases and has been
implicated in a wide range of cellular processes and signaling
activities as well as in the control of normal cell growth, and when
hyperactivated, in cellular transformation [29]. Cdc42 is a down-
stream target of EGFR that activates Cdc42 by phosphorylation.
Previous evidence suggests that a positive feedback loop may exist
between Cdc42 and EGFR. Treatment of cells with EGF stimulates
the activation of Cdc42 [30]. Activated Cdc42, through an interac-
tion with Cool-1, inhibits the binding of c-Cbl ubiquitin ligase to
EGFR and thus leads to the aberrant accumulation of EGFR and
results in malignant transformation [24].
Lin et al. reported that a novel Cdc42 mutant Cdc42(F28L), was
capable of spontaneous GDP-GTP exchange and exhibited severalAnti-BrdU Nucleus
re performed on NIH 3T3 cells stably expressing Cdc42(F28L) or Cdc42(F28Lss). (A)
average of three independent experiments. (B) Immunoﬂuorescence microscopy
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Fig. 6. Activated Cdc42 promotes EGFR nuclear transport and accumulation. (A) Nuclear and cytoplasmic fractions from NIH 3T3 cells stably expressing Cdc42(F28L),
Cdc42(F28Lss) or vector control cells were subjected to Western blot with antibodies against EGFR and lamin B. Lamin B was used as a marker for the nucleus. (B) NIH 3T3
cells stably expressing Cdc42(F28L), Cdc42(F28Lss) or vector control cells were immunostained with EGFR antibody (red) and the nuclei of cells were stained with DAPI
(blue), and analyzed using confocal microscopy. Scale bars: 5 lm. Equivalent amounts of proteins were loaded to the gel.
X.-Y. Wang et al. / FEBS Letters 589 (2015) 255–262 261hallmarks of cell transformation-reduced contact inhibition, lower
dependence on serum for growth and anchorage-independent
growth [9]. However, when two lysine residues in position 183
and 184 were mutated to serine in Cdc42(F28L) background, this
mutant Cdc42(F28Lss) did not transform the cells. To ﬁgure out
the molecular mechanism, we used this mutant to eliminate
Cdc42 binding to cCOP [8]. We found that Cdc42(F28Lss) fails to
induce EGFR accumulation, consequently, EGF-induced activation
of ERK, Akt, and JNK signals by Cdc42(F28L) were not sustained
in Cdc42(F28Lss)-expressing cells. cCOP in conjunction with the
GTP binding protein ARF1, forms an electron-dense coat that, when
assembled onto Golgi membranes, is thought to facilitate mem-
brane budding and ﬁssion events associated with Golgi membrane
trafﬁc [31]. EGF-dependent nuclear transport of EGFR is regulated
by retrograde trafﬁcking from the Golgi to the ER involving an
association of EGFR with cCOP, one of the subunits of the COP I
coatomer [32]. Taken together, we found a new molecular mecha-
nism for Cdc42 induced cellular transformation by which Cdc42
accumulates EGFR and induces cell transformation through
increased intracellular trafﬁcking. This mechanism is different
from other people’s ﬁnding in which EGFR accumulation was asso-
ciated with c-Cbl lost function for EGFR ubiquitination and
degradation.
Multiple cell surface receptor tyrosine kinases have been
reported to, localize in the nucleus. Accruing evidence points to a
scenario where nuclear localization of EGFR in different tumor
types has impact on not only the tumor grade but also on the resis-
tance of tumors to therapies [33]. Endocytosis has been proven to
be required for the nuclear translocation of EGFR, but after endocy-
tosis the EGF-dependent nuclear transport of EGFR is regulated by
a retrograde trafﬁcking from Golgi to the ER involved an associa-tion of EGFR with cCOP [34], cCOP can bind to Cdc42 [12]. It has
not been investigated whether Cdc42 can regulate EGFR nuclear
transport. In this study, we proved evidence to suggest that acti-
vated Cdc42 promotes more EGFR to enter into the nucleus. Our
confocal microscopy study further conﬁrmed that more EGFR
was accumulated in nuclei of Cdc42(F28L) expressing cells than
those of Cdc42(F28Lss) expressing cells.
In conclusion, our study reveals a novel mechanism by which
disrupting the interaction between constitutively active Cdc42
and the coatomer subunit cCOP inhibits transformed phenotypes,
and demonstrates for the ﬁrst time that Cdc42 can promote EGFR
nuclear transport and accumulation. These ﬁndings may provide
new insight for understanding the resistance of tumors to EGFR
therapies.Acknowledgements
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